Patents by Inventor Kathleen S. Keegan
Kathleen S. Keegan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10111882Abstract: The application provides methods of treating or reducing thrombocytopenia, leukopenia, anemia, or neutropenia in a patient in need thereof, comprising the step of administering an effective amount of a compound selected from Compounds 1-6, disclosed herein.Type: GrantFiled: September 14, 2017Date of Patent: October 30, 2018Assignee: GILEAD SCIENCES, INC.Inventors: Esteban M. Abella, Julie A. Di Paolo, Kathleen S. Keegan, Antonio Mario Querido Marcondes, Yang Pan, Arati V. Rao
-
Publication number: 20180071302Abstract: The application provides methods of treating or reducing thrombocytopenia, leukopenia, anemia, or neutropenia in a patient in need thereof, comprising the step of administering an effective amount of a compound selected from Compounds 1-6, disclosed herein.Type: ApplicationFiled: September 14, 2017Publication date: March 15, 2018Inventors: Esteban M. Abella, Julie A. Di Paolo, Kathleen S. Keegan, Antonio Mario Querido Marcondes, Yang Pan, Arati V. Rao
-
Publication number: 20160368933Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.Type: ApplicationFiled: April 22, 2016Publication date: December 22, 2016Inventors: Xiaoqi CHEN, Kang DAI, Jason DUQUETTE, Michael W. GRIBBLE, JR., Justin N. HUARD, Kathleen S. KEEGAN, Zhihong LI, Sarah E. LIVELY, Lawrence R. MCGEE, Mark L. RAGAINS, Xianghong WANG, Margaret F. WEIDNER, Jian ZHANG
-
Patent number: 9359355Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.Type: GrantFiled: November 25, 2013Date of Patent: June 7, 2016Assignee: AMGEN INC.Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, Jr., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
-
Publication number: 20140163052Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.Type: ApplicationFiled: November 25, 2013Publication date: June 12, 2014Applicant: AMGEN INC.Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, JR., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
-
Patent number: 8623885Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.Type: GrantFiled: March 21, 2012Date of Patent: January 7, 2014Assignee: Amgen Inc.Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, Jr., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
-
Publication number: 20120244110Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.Type: ApplicationFiled: March 21, 2012Publication date: September 27, 2012Applicant: Amgen Inc.Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, JR., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
-
Publication number: 20100105683Abstract: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.Type: ApplicationFiled: September 1, 2009Publication date: April 29, 2010Inventors: Kathleen S. Keegan, Edward A. Kesicki, John Joseph Gaudino, Adam Wade Cook, Scott Douglas Cowen, Laurence Edward Burgess
-
Patent number: 7067506Abstract: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.Type: GrantFiled: March 1, 2002Date of Patent: June 27, 2006Assignee: ICOS CorporationInventors: Kathleen S. Keegan, Edward A. Kesicki, John Joseph Gaudino, Adam Wade Cook, Scott Douglas Cowen, Laurence Edward Burgess
-
Patent number: 6815532Abstract: Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.Type: GrantFiled: September 21, 2001Date of Patent: November 9, 2004Assignee: ICOS CorporationInventors: Kate Loughney, Kathleen S. Keegan
-
Publication number: 20030069284Abstract: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.Type: ApplicationFiled: March 1, 2002Publication date: April 10, 2003Inventors: Kathleen S. Keegan, Edward A. Kesicki, John Joseph Gaudino, Adam Wade Cook, Scott Douglas Cowen, Laurence Edward Burgess
-
Publication number: 20030023055Abstract: Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.Type: ApplicationFiled: September 21, 2001Publication date: January 30, 2003Applicant: ICOS CorporationInventors: Kate Loughney, Kathleen S. Keegan
-
Publication number: 20020197712Abstract: The present invention relates generally to a novel CREBa polypeptide isoform, polynucleotides encoding the polypeptide, expression constructs comprising the polynucleotides, host cell transformed or transfected with the polynucleotides, methods for producing the polypeptide, and methods to identify inhibitors of binding between the CREBa and other polypeptides or polynucleotides.Type: ApplicationFiled: June 19, 2001Publication date: December 26, 2002Applicant: ICOS CorporationInventor: Kathleen S. Keegan
-
Patent number: 6344549Abstract: Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.Type: GrantFiled: October 14, 1999Date of Patent: February 5, 2002Assignee: ICOS CorporationInventors: Kate Loughney, Kathleen S. Keegan
-
Patent number: 6248532Abstract: The present invention relates generally to a novel CREBa polypeptide isoform, polynucleotides encoding the polypeptide, expression constructs comprising the polynucleotides, host cell transformed or transfected with the polynucleotides, methods for producing the polypeptide, and methods to identify inhibitors of binding between the CREBa and other polypeptides or polynucleotides.Type: GrantFiled: September 28, 1999Date of Patent: June 19, 2001Assignee: ICOS CorporationInventor: Kathleen S. Keegan
-
Patent number: 5959079Abstract: The present invention relates generally to a novel CREBa polypeptide isoform, polynucleotides encoding the polypeptide, expression constructs comprising the polynucleotides, host cell transformed or transfected with the polynucleotides, methods for producing the polypeptide, and methods to identify inhibitors of binding between the CREBa and other polypeptides or polynucleotides.Type: GrantFiled: January 12, 1998Date of Patent: September 28, 1999Assignee: ICOS CorporationInventor: Kathleen S. Keegan
-
Patent number: 5854016Abstract: The present invention relates generally to a novel CREBa polypeptide isoform, polynucleotides encoding the polypeptide, expression constructs comprising the polynucleotides, host cell transformed or transfected with the polynucleotides, methods for producing the polypeptide, and methods to identify inhibitors of binding between the CREBa and other polypeptides or polynucleotides.Type: GrantFiled: September 27, 1996Date of Patent: December 29, 1998Assignee: ICOS CorporationInventor: Kathleen S. Keegan